Next Article in Journal
Mechanistic Insight into Long Noncoding RNAs and the Placenta
Next Article in Special Issue
Analysis of Hypericin-Mediated Effects and Implications for Targeted Photodynamic Therapy
Previous Article in Journal
Allergens with Protease Activity from House Dust Mites
Previous Article in Special Issue
Montelukast Induces Apoptosis-Inducing Factor-Mediated Cell Death of Lung Cancer Cells
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessCommentary
Int. J. Mol. Sci. 2017, 18(7), 1374; doi:10.3390/ijms18071374

The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy

1
Institute for the Experimental Endocrinology and Oncology “G. Salvatore”, Italian National Council of Research, via S. Pansini 5, 80131 Napoli, Italy
2
Thoracic Surgery Unit, Antonio Cardarelli Hospital, via A. Cardarelli 9, 80131 Napoli, Italy
*
Authors to whom correspondence should be addressed.
Received: 5 June 2017 / Revised: 23 June 2017 / Accepted: 25 June 2017 / Published: 27 June 2017
(This article belongs to the Special Issue Tumor Targeting Therapy and Selective Killing)
View Full-Text   |   Download PDF [205 KB, uploaded 27 June 2017]

Abstract

Lung cancer is the most common cancer worldwide. Disappointingly, despite great effort in encouraging screening or, at least, a close surveillance of high-risk individuals, most of lung cancers are diagnosed when already surgically unresectable because of local advancement or metastasis. In these cases, the treatment of choice is chemotherapy, alone or in combination with radiotherapy. Here, we will briefly review the most successful and recent advances in the identification of novel lung cancer genetic lesions and in the development of new drugs specifically targeting them. However, lung cancer is still the leading cause of cancer-related mortality also because, despite impressive initial responses, the patients often develop resistance to novel target therapies after a few months of treatment. Thus, it is literally vital to continue the search for new therapeutic options. So, here, on the basis of our recent findings on the role of the tumor suppressor CCDC6 protein in lung tumorigenesis, we will also discuss novel therapeutic approaches we envision for lung cancer. View Full-Text
Keywords: lung neoplasms; antineoplastic agents; biomarkers; poly(ADP-ribose) polymerase inhibitors; CCDC6 lung neoplasms; antineoplastic agents; biomarkers; poly(ADP-ribose) polymerase inhibitors; CCDC6
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Visconti, R.; Morra, F.; Guggino, G.; Celetti, A. The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. Int. J. Mol. Sci. 2017, 18, 1374.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top